Article

Evidence-based approach to eye care analyzed

The greatest preoperative risk factor for CME is diabetes—the risk of developing post-cataract extraction CME has been reported to be as high as 60% in diabetics.

The program, held during the annual meeting of the American Academy of Ophthalmology, was jointly sponsored by the New York Eye and Ear Infirmary and Ophthalmology Times and supported by an unrestricted educational grant from Allergan.

Dr. Simmons summarized the findings from a number of trials. Two clinical trials comparing latanoprost (Xalatan, Pfizer) and travoprost (Travatan, Alcon) found that the two drugs are relatively equal in effectiveness except that travoprost achieves maximum efficacy somewhat more quickly. Both also show a slight dip in afternoon pressure control, he said.

Four clinical trials have compared latanoprost and bimatoprost (Lumigan, Allergan), with similar results. They found that the drugs are equivalent in IOP-lowering at 8 a.m. but that bimatoprost is more effective in the afternoon and evening.

Three comparisons of bimatoprost and travoprost have shown that bimatoprost is more effective in lowering IOP.

In summarizing the findings of both these drug studies and large trials studying various aspects of progression and treatment, Dr. Simmons outlined several strategies for physicians.

"To be successful at treating glaucoma today, we need to lower IOP consistently and aggressively. The hypotensive lipids are clearly the most effective class of medication to achieve that goal. And when one looks at the weight of evidence in numerous trials, bimatoprost appears to be the most effective in lowering IOP and has the fewest nonresponders, the best diurnal pressure control, and equal or better compliance and adherence," Dr. Simmons said.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.